Background: The annual standard-dose (SD) influenza vaccine has suboptimal immunogenicity in solid organ transplant recipients (SOTRs). Influenza vaccine that contains higher doses of antigens may lead to greater immunogenicity in this population. Methods: We conducted a randomized, double-blind trial to compare the safety and immunogenicity of the 2016-2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) influenza vaccine in adult SOTRs. Preimmunization and 4-week postimmunization sera underwent strain-specific hemagglutination inhibition assay. Results: We enrolled 172 patients who received study vaccine, and 161 (84 HD; 77 SD) were eligible for analysis. Seroconversion to at least 1 of 3 vaccine antigens was present in 78.6% vs 55.8% in HD vs SD vaccine groups (P < .001), respectively. Seroconversions to A/ H1N1, A/H3N2, and B strains were 40.5% vs 20.5%, 57.1% vs 32.5%, and 58.3% vs 41.6% in HD vs SD vaccine groups (P = .006, P = .002, P = .028, respectively). Post-immunizationgeometric mean titers of A/H1N1, A/H3N2, and B strains were significantly higher in the HD group (P = .007, P = .002, P = .033). Independent factors associated with seroconversion to at least 1 vaccine strain were the use of HD vaccine (odds ratio [OR], 3.23; 95% confidence interval [CI], 1.56-6.67) and use of mycophenolate doses <2 g daily (OR, 2.76; 95% CI, 1.12-6.76). Conclusions: HD vaccine demonstrated significantly better immunogenicity than SD vaccine in adult transplant recipients and may be the preferred influenza vaccine for this population. Clinical Trials Registration: NCT03139565.
RCT Entities:
Background: The annual standard-dose (SD) influenza vaccine has suboptimal immunogenicity in solid organ transplant recipients (SOTRs). Influenza vaccine that contains higher doses of antigens may lead to greater immunogenicity in this population. Methods: We conducted a randomized, double-blind trial to compare the safety and immunogenicity of the 2016-2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) influenza vaccine in adult SOTRs. Preimmunization and 4-week postimmunization sera underwent strain-specific hemagglutination inhibition assay. Results: We enrolled 172 patients who received study vaccine, and 161 (84 HD; 77 SD) were eligible for analysis. Seroconversion to at least 1 of 3 vaccine antigens was present in 78.6% vs 55.8% in HD vs SD vaccine groups (P < .001), respectively. Seroconversions to A/ H1N1, A/H3N2, and B strains were 40.5% vs 20.5%, 57.1% vs 32.5%, and 58.3% vs 41.6% in HD vs SD vaccine groups (P = .006, P = .002, P = .028, respectively). Post-immunization geometric mean titers of A/H1N1, A/H3N2, and B strains were significantly higher in the HD group (P = .007, P = .002, P = .033). Independent factors associated with seroconversion to at least 1 vaccine strain were the use of HD vaccine (odds ratio [OR], 3.23; 95% confidence interval [CI], 1.56-6.67) and use of mycophenolate doses <2 g daily (OR, 2.76; 95% CI, 1.12-6.76). Conclusions: HD vaccine demonstrated significantly better immunogenicity than SD vaccine in adult transplant recipients and may be the preferred influenza vaccine for this population. Clinical Trials Registration: NCT03139565.
Authors: Christopher Robson; Sai Rupa Baskar; Robert Booy; Patricia E Ferguson; Nicole Gilroy; Jen Kok; Indy Sandaradura; Dominic Dwyer Journal: Aust Prescr Date: 2019-04-01
Authors: Carol M Kao; Kristina Lai; John M McAteer; Mohnd Elmontser; Elizabeth M Quincer; Marianne E M Yee; Ashley Tippet; Robert C Jerris; Peter A Lane; Evan J Anderson; Nitya Bakshi; Inci Yildirim Journal: Pediatr Blood Cancer Date: 2020-05-29 Impact factor: 3.167
Authors: David Cucchiari; Natalia Egri; Marta Bodro; Sabina Herrera; Jimena Del Risco-Zevallos; Joaquim Casals-Urquiza; Frederic Cofan; Asunción Moreno; Jordi Rovira; Elisenda Banon-Maneus; Maria J Ramirez-Bajo; Pedro Ventura-Aguiar; Anna Pérez-Olmos; Marta Garcia-Pascual; Mariona Pascal; Anna Vilella; Antoni Trilla; José Ríos; Eduard Palou; Manel Juan; Beatriu Bayés; Fritz Diekmann Journal: Am J Transplant Date: 2021-08-04 Impact factor: 9.369
Authors: Kailey Hughes; Donald B Middleton; Mary Patricia Nowalk; Goundappa K Balasubramani; Emily T Martin; Manjusha Gaglani; H Keipp Talbot; Manish M Patel; Jill M Ferdinands; Richard K Zimmerman; Fernanda P Silveira Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 9.079